These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 26927284)
1. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. Graziano F; Ruzzo A; Giacomini E; Ricciardi T; Aprile G; Loupakis F; Lorenzini P; Ongaro E; Zoratto F; Catalano V; Sarti D; Rulli E; Cremolini C; De Nictolis M; De Maglio G; Falcone A; Fiorentini G; Magnani M Pharmacogenomics J; 2017 Jun; 17(3):258-264. PubMed ID: 26927284 [TBL] [Abstract][Full Text] [Related]
2. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N J BUON; 2015; 20(1):128-35. PubMed ID: 25778307 [TBL] [Abstract][Full Text] [Related]
3. Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. Ruzzo A; Graziano F; Bagaloni I; Di Bartolomeo M; Prisciandaro M; Aprile G; Ongaro E; Vincenzi B; Perrone G; Santini D; Fornaro L; Vivaldi C; Tomasello G; Loupakis F; Lonardi S; Fassan M; Valmasoni M; Sarti D; Lorenzini P; Catalano V; Bisonni R; Del Prete M; Collina G; Magnani M Gastric Cancer; 2020 Nov; 23(6):1064-1074. PubMed ID: 32372141 [TBL] [Abstract][Full Text] [Related]
4. RRAD inhibits aerobic glycolysis, invasion, and migration and is associated with poor prognosis in hepatocellular carcinoma. Shang R; Wang J; Sun W; Dai B; Ruan B; Zhang Z; Yang X; Gao Y; Qu S; Lv X; Tao K; Wang L; Dou K; Wang D Tumour Biol; 2016 Apr; 37(4):5097-105. PubMed ID: 26546438 [TBL] [Abstract][Full Text] [Related]
5. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759 [TBL] [Abstract][Full Text] [Related]
6. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936 [TBL] [Abstract][Full Text] [Related]
7. Morphological aspects of the hepatic response to neoadjuvant therapy. Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186 [TBL] [Abstract][Full Text] [Related]
8. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Azuma M; Shi M; Danenberg KD; Gardner H; Barrett C; Jacques CJ; Sherod A; Iqbal S; El-Khoueiry A; Yang D; Zhang W; Danenberg PV; Lenz HJ Pharmacogenomics; 2007 Dec; 8(12):1705-13. PubMed ID: 18086000 [TBL] [Abstract][Full Text] [Related]
9. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis. Koi M; Garcia M; Choi C; Kim HR; Koike J; Hemmi H; Nagasaka T; Okugawa Y; Toiyama Y; Kitajima T; Imaoka H; Kusunoki M; Chen YH; Mukherjee B; Boland CR; Carethers JM Gastroenterology; 2016 Apr; 150(4):944-55. PubMed ID: 26752111 [TBL] [Abstract][Full Text] [Related]
10. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320 [TBL] [Abstract][Full Text] [Related]
12. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674 [TBL] [Abstract][Full Text] [Related]
13. Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. Baba H; Baba Y; Uemoto S; Yoshida K; Saiura A; Watanabe M; Maehara Y; Oki E; Ikeda Y; Matsuda H; Yamamoto M; Shimada M; Taketomi A; Unno M; Sugihara K; Ogata Y; Eguchi S; Kitano S; Shirouzu K; Saiki Y; Takamori H; Mori M; Hirata T; Wakabayashi G; Kokudo N Oncotarget; 2015 Oct; 6(32):34004-13. PubMed ID: 26372896 [TBL] [Abstract][Full Text] [Related]
14. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer. Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625 [TBL] [Abstract][Full Text] [Related]
15. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Matsuyama R; Togo S; Shimizu D; Momiyama N; Ishikawa T; Ichikawa Y; Endo I; Kunisaki C; Suzuki H; Hayasizaki Y; Shimada H Int J Cancer; 2006 Jul; 119(2):406-13. PubMed ID: 16477629 [TBL] [Abstract][Full Text] [Related]
16. Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Wang J; Wang H; Liu A; Fang C; Hao J; Wang Z Oncotarget; 2015 Aug; 6(23):19456-68. PubMed ID: 26062441 [TBL] [Abstract][Full Text] [Related]
17. New strategies for targeting glucose metabolism-mediated acidosis for colorectal cancer therapy. Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL J Cell Physiol; 2018 Jan; 234(1):348-368. PubMed ID: 30069931 [TBL] [Abstract][Full Text] [Related]
18. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816 [TBL] [Abstract][Full Text] [Related]
19. Metabolic phenotype of bladder cancer. Massari F; Ciccarese C; Santoni M; Iacovelli R; Mazzucchelli R; Piva F; Scarpelli M; Berardi R; Tortora G; Lopez-Beltran A; Cheng L; Montironi R Cancer Treat Rev; 2016 Apr; 45():46-57. PubMed ID: 26975021 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients. Liu X; Yao D; Liu C; Cao Y; Yang Q; Sun Z; Liu D Tumour Biol; 2016 Jun; 37(6):8367-74. PubMed ID: 26733163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]